Business Wire

Semperis Brings Award-Winning Hybrid Identity Protection Conference to Europe, Keynotes Announced

12.5.2021 11:00:00 EEST | Business Wire | Press release

Share

Semperis, the pioneer in identity-driven cyber resilience for enterprises, today announced that it will host the inaugural Hybrid Identity Protection (HIP) Europe Virtual Conference 2021, taking place virtually on 30 June and 1 July 2021. The first European edition of the award-winning global Hybrid Identity Protection conference series, HIP Europe will bring together leading experts working at the intersection between identity and security to provide a deep dive into the latest trends and challenges in managing hybrid and multi-cloud environments.

Keynote speakers will include Microsoft MVP Tony Redmond, aka the Exchange Godfather and author of numerous books and blogs on Microsoft Exchange and Office 365, and Microsoft Directory Services MVP and identity guru John Craddock, who has played a key role architecting identity and security solutions for industry leaders including Microsoft, the UK Government and multi-national businesses.

Organisations globally are struggling to keep up with the skyrocketing proliferation of cyberattacks — including the infamous SolarWinds supply-chain attack and the Hafnium attack on Microsoft Exchange — that target identity systems, especially Active Directory. HIP Europe will connect technology gurus and practitioners in an environment where they can exchange information, share war stories, and ultimately make their networks and applications more secure.

The HIP conference has earned its place as the premier educational forum for identity-centric cybersecurity leaders tasked with defending hybrid environments. First established in the US and now coming to Europe, the conference series is designed to advance the skills of IT and cybersecurity professionals through highly technical demonstrations, expert roundtables, and networking sessions. Attendees will learn best practices from local identity and access management (IAM) experts and Microsoft Most Valuable Professionals (MVPs), and connect with peers facing similar infrastructure and security challenges.

Agenda highlights

The two-day conference programme is packed with actionable insights for practitioners, from discussing the future of cloud security to identifying and recovering from directory breaches and cyber disasters. Highlights include:

  • The Future of Microsoft Cloud Services. In this keynote session, Tony Redmond will look at the economics, software engineering, ecosystem and landscape of Microsoft 365 and discuss the reliability and security of Office 365.
  • The Future of Identity: DIDs and VCs. This keynote by John Craddock will be an introduction to the future of identity with Decentralised Identifiers (DIDs) and Verifiable Credentials (VCs). What if users owned their identity without dependence on identity providers and only needed to prove who they are once, using that proof as often as necessary?
  • Cloud Security: What’s Next? Providing a simple and unified hybrid security management engine that spans the heterogeneous space of on-premises, shared data centre and cloud is a key challenge. This session will sketch the current cloud security landscape and what challenges lie ahead for hybrid organisations.
  • Deploying a Zero Trust Infrastructure. This session will demonstrate how to implement the principles of Zero Trust within a Microsoft hybrid cloud infrastructure, building on the Microsoft security stack with Azure AD, Control and Conditional Access Management features and Microsoft 365 Defender suite.

Keynote speaker and identity guru John Craddock comments: “Almost all organisations consume services from the cloud and are possibly shifting their own services to the cloud, building valuable collaborative environments providing access for their users, partners and consumers. The security boundary stretches and morphs as we create these new hybrid systems. With these elastic boundaries, identity becomes the critical component in securing our assets and managing access control. At the Hybrid Identity Protection conference, attendees can learn from industry leaders how to identify potential vulnerabilities and protect their systems for the future. A paradigm shift is around the corner with Decentralised Identity and Verifiable Credentials. My keynote will explain the benefits of this exciting new technology.”

Guido Grillenmeier, Chief Technologist at Semperis and Microsoft MVP alumnus for Directory Services, adds: “We’re excited to bring the HIP conference to Europe for the first time. It promises an amazing line-up of the world’s foremost hybrid identity experts covering today’s hottest identity security topics: the future of cloud services, cloud security and identity itself. Zero Trust is the name of the game when it comes to preventing malicious actors from stealing the keys to your kingdom – your most privileged accounts – be it on-premises or in the cloud. HIP Europe will give solid insights into how it is done right. Due to the pandemic, this will be a fully virtual experience, and it is free to attend. Security professionals can expect to discuss learnings from recent cyber incidents, experiences in recovering from attacks and how to defend modern environments against emerging threats.”

The global HIP event was established by Semperis in 2016 and has won several awards, including the 2021 Globee Business Awards – Gold Winner, Achievement of the Year in Live Events, the 2020 Cybersecurity Excellence Awards – Best Cybersecurity Conference, the Golden Bridge Business and Innovation Awards – Gold Winner, Live Event of the Year, and the 2020 IT World Awards – Bronze Winner, Security Awareness Computer-Based Training.

HIP Europe attendees can qualify for up to 12 continuing professional education (CPE) credits.

The full conference agenda is available: https://www.accelevents.com/e/HIPEurope#agenda

Registration is free: https://www.accelevents.com/e/u/checkout/HIPEurope/tickets/order

About Hybrid Identity Protection

Mobile workforces, cloud applications and digitalisation are changing every aspect of the modern enterprise. And with radical transformation come new business risks. Hybrid Identity Protection (HIP) is the premier educational forum for identity-centric practitioners. Whatever industry sector or job function, HIP strives to provide its community the insights and relationships needed to enable and protect today’s digitally driven organisations.

Twitter https://twitter.com/HIPConf
LinkedIn https://www.linkedin.com/company/hybrid-identity-protection-conference/
Facebook https://www.facebook.com/HIPConf/

About Semperis

For security teams charged with defending hybrid and multi-cloud environments, Semperis ensures integrity and availability of critical enterprise directory services at every step in the cyber kill chain and cuts recovery time by 90%. Purpose-built for securing Active Directory, Semperis’ patented technology protects over 40 million identities from cyberattacks, data breaches, and operational errors. The world’s leading organisations trust Semperis to spot directory vulnerabilities, intercept cyberattacks in progress, and quickly recover from ransomware and other data integrity emergencies. Semperis is headquartered in New Jersey and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.

Semperis hosts the award-winning Hybrid Identity Protection conference (www.hipconf.com). The company has received the highest level of industry accolades and was recently ranked the fourth fastest-growing company in the tri-state area and 35th overall in Deloitte’s 2020 Technology Fast 500™. Semperis is accredited by Microsoft and recognised by Gartner.

Twitter https://twitter.com/SemperisTech
LinkedIn https://www.linkedin.com/company/semperis
Facebook https://www.facebook.com/SemperisTech
YouTube https://www.youtube.com/channel/UCycrWXhxOTaUQ0sidlyN9SA

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paula Averley
Origin Communications
E. semperis@origincomms.com
T. +44 (0)20 3814 2940

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye